Assessing the Safety of Dapivirine Gel and Film Formulations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The safety/toxicity endpoint is clinical or laboratory evidence of a Grade 2 or higher Adverse Event as defined by the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 and the Female Genital Grading Table for Use in Microbicide Studies which is judged to be related to study product.

Secondary Outcome Measures
:

Changes in vaginal flora and vaginal pH [ Time Frame: 5-11 weeks ]

Systemic and local absorption levels of dapivirine [ Time Frame: 5-11 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 45 Years (Adult)

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Age 18 through 45 years (inclusive) at screening

Able and willing to provide written informed consent to be screened for and to take part in the study.

Able and willing to provide adequate locator information

HIV-uninfected based on testing performed by study staff at screening (per algorithm in Appendices I)

Per participant report, using an effective method of contraception at enrollment; hormonal method (except vaginal ring) used continuously for the past 30 days; intrauterine device (IUD inserted at least 30 days prior to enrollment); female sterilization; abstinent from sexual activity with male partner for the past 30 days; or sexual activity with vasectomized partner; and willingness to use effective method of contraception until the completion of final scheduled study visit if enrolled (approximately 35 days after enrollment)

In general good health as determined by the site clinician

For participants older than 21, a pap result in the 12 calendar months prior to Enrollment consistent with Grade 0 according to the Female Genital Grading Table for Use in Microbicide Studies Addendum 1 to the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009) or satisfactory evaluation with no treatment required of non-Grade 0 Pap result per American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines or per local standard of care, in the 12 calendar months prior to the Enrollment

Note: For participants aged 18-21, a Grade-0 or adequately evaluated abnormal Pap smear is not required as the American Society for Colposcopy and Cervical Pathology recommends initiating screening at age 21.

Agree to be sexually abstinent from Visit 1 until the completion of Visit 3

Agree to use study condoms between Visits 3 and 4 (if heterosexually active)

Agree to abstain from any other intravaginal product or penetration (including sex toys, excluding tampons) until Visit 3

Willingness to undergo all study-related assessments and follow all study-related procedures

At screening and enrollment, agrees not to participate in other research studies involving drugs, medical devices, or vaginal products while enrolled in this trial

Exclusion Criteria:

Menopause (as defined as amenorrhea for one year or more without an alternative etiology)

Hysterectomy

Participant report of any of the following:

Known adverse reaction to any of the study products (ever)

Known adverse reaction to latex (ever)

Non- therapeutic injection drug use in the 12 months prior to Screening

Surgical procedure involving the pelvis in the 90 days prior to enrollment (includes dilation and curettage or evacuation, and cryosurgery; does not include cervical biopsy for evaluation of an abnormal pap smear)

Participation in a drug, spermicide and/or microbicide study in the 30 days prior to enrollment or anticipated participation in an investigational drug study in the next 8 weeks

Pregnancy within 90 days of enrollment

Currently lactating

Use of a diaphragm, NuvaRing®, or spermicide for contraception

Internal vaginal use of any device or product (except tampons) in the 7 days prior to enrollment

Has any of the following laboratory abnormalities per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 December 2004:

Grade 1 or higher AST or ALT

Grade 1 or higher creatinine

Grade 2 or higher hemoglobin

Grade 1 or higher platelets (Note: otherwise eligible participants with an exclusionary test may be re-tested during the screening process).

Any condition that, in the opinion of the Investigator, would preclude provision of consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives